Last C$0.07 CAD
Change Today +0.01 / 16.67%
Volume 38.3K
VPT On Other Exchanges
Symbol
Exchange
Venture
OTC US
As of 3:21 PM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

ventripoint diagnostics ltd (VPT) Snapshot

Open
C$0.07
Previous Close
C$0.06
Day High
C$0.07
Day Low
C$0.07
52 Week High
03/10/14 - C$0.17
52 Week Low
11/18/13 - C$0.03
Market Cap
12.5M
Average Volume 10 Days
68.9K
EPS TTM
C$-0.02
Shares Outstanding
178.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VENTRIPOINT DIAGNOSTICS LTD (VPT)

Related News

No related news articles were found.

ventripoint diagnostics ltd (VPT) Related Businessweek News

No Related Businessweek News Found

ventripoint diagnostics ltd (VPT) Details

VentriPoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools to monitor patients with heart disease primarily in Canada and Europe. The company offers VentriPoint Diagnostic System that is used to generate critical shape and volume measurements of the right ventricle. Its VentriPoint Diagnostic System consists of commercial off-the-shelf computer and tracking system sensor, as well as patented and proprietary methods, and software. VentriPoint Diagnostics Ltd. is based in Calgary, Canada.

ventripoint diagnostics ltd (VPT) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $227.3K
Chief Financial Officer and Vice President
Total Annual Compensation: --
Compensation as of Fiscal Year 2012.

ventripoint diagnostics ltd (VPT) Key Developments

VentriPoint Diagnostics Ltd. Announces Resignation of Don Black as Director

VentriPoint Diagnostics Ltd. announced that Don Black has resigned as a Director of the company for health reasons.

VentriPoint Diagnostics Announces VMS Heart Analysis System to Monitor Therapy in Pulmonary Hypertension and Valve Replacement in Congenital Heart Disease

VentriPoint Diagnostics Ltd. announced that following the clearance by the US Food and Drug Administration (FDA) of the VMS(TM) heart analysis system for right ventricle assessment in adult patients with Pulmonary Arterial Hypertension (PAH), the Company has focused on advancing marketing strategies, furthering partnership discussions for technology integration and establishing clinical studies to broaden the application of the VMS. The company report on the completion of two studies, one in PAH and one in congenital heart disease. Both studies verify the utility of the VMS(TM) in monitoring patients after treatment to determine if the therapy has been effective. Right heart function remains a significant prognostic parameter for all heart disease. The recent clearance has paved the way to further product's value by expanding its application to all major heart conditions. The company developed a regulatory strategy and although it is difficult to gauge timelines for FDA processes, The company anticipates utilizing the Special 510(k) process using the VMS(TM) as the predicate device, and expect additional applications will be approved by the 3rd quarter this year.

FDA Clears VentriPoint Diagnostics Ltd.'s VMS(TM) Heart Analysis System for Use in Patients with Pulmonary Arterial Hypertension

VentriPoint Diagnostics Ltd. announced that the US Food and Drug Administration (FDA) has cleared the VMS(TM) heart analysis system to be an adjunct to all existing 2D ultrasound imaging devices to allow computation of the 3D volume and ejection fraction of the right heart in patients with Pulmonary Arterial Hypertension (PAH). Right heart function remains one of the most significant prognostic parameters in PAH. The VMS heart analysis system enables physicians to quickly and non-invasively determine the size and function of the right heart - transforming patient care and reducing healthcare costs. PAH can occur for no known reason but will typically occur in association with many common conditions such as chronic liver disease and liver cirrhosis; connective tissue disorders such as scleroderma or systemic lupus erythematosus (lupus); congenital heart disease (even if repaired) and HIV. PAH is the serious form of the five recognized groups of pulmonary hypertension and is a devastating disease with an average patient lifespan of less than 3 years after diagnosis if untreated. It affects individuals from infancy to the elderly. Although treatment started early after detection appears more effective than when started later, the majority of patients with PAH continue to be diagnosed too late for treatment to be fully effective. With increasing availability of effective therapies, and evidence-based treatment guidelines recommending frequent monitoring, functional tests should prove invaluable for managing patients with PAH. The VMS(TM) is approved for clinical use in PAH patients in Canada and Europe, and now in the United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VPT:CN C$0.07 CAD +0.01

VPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VPT.
View Industry Companies
 

Industry Analysis

VPT

Industry Average

Valuation VPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 106.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 107.3x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VENTRIPOINT DIAGNOSTICS LTD, please visit www.ventripoint.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.